← Browse by Condition
Medical Condition

tislelizumab

Total Trials
3
Recruiting Now
3
Trial Phases
Phase 2

ClinicalMetric tracks all active clinical trials for tislelizumab sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — tislelizumab Clinical Trials

How many clinical trials are currently recruiting for tislelizumab?
ClinicalMetric currently tracks 3 actively recruiting clinical trials for tislelizumab, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 3. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for tislelizumab?
tislelizumab research spans Phase 2 (3 trials). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a tislelizumab clinical trial?
Eligibility criteria for tislelizumab trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 2
3
Top Sponsors
Seventh Medical Center of PLA General Hospital 1 trial
Zibo Municipal Hospital 1 trial
Chuangzhen Chen 1 trial

Recruiting Clinical Trials

NCT07458529 Phase 2
Recruiting
Neoadjuvant Chemoradiotherapy Plus Tislelizumab With or Without Probio-M9 in pMMR/MSS Locally Advanced Rectal Cancer
Enrollment
50 pts
Location
China
Sponsor
Seventh Medical Center of PLA ...
View Trial →
NCT07085182 Phase 2
Recruiting
Tislelizumab Combined With sCRT in Stage IIIB/C-IV Non-Squamous Non-Small Cell Lung Cancer:A Prospective, Single-Arm, Phase II Study
Enrollment
20 pts
Location
China
Sponsor
Zibo Municipal Hospital
View Trial →
NCT07339488 Phase 2
Recruiting
Intestinal Low-Dose Radiotherapy Plus Immunochemotherapy for Conversion of Borderline Resectable/Unresectable Esophageal Squamous Cell Carcinoma
Enrollment
39 pts
Location
China
Sponsor
Chuangzhen Chen
View Trial →

Related Conditions

chemotherapy (2) rectal cancer adenocarcinoma (1) neoadjuvant therapy (1) immunotherapy (1) probio m9 (1) randomized (1) nsclc (1) hypofractionated radiotherapy (1) borderline resectable carcinoma (1) unresectable cancer (1) esophageal squamous cell carcinoma escc (1) immune checkpoint inhibitor (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: November 2026  ·  Data Methodology